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Purpose: The prevalence of HCV infection has increased during recent years and the incidence reach 3% of the
world's population, and in some countries like Egypt, may around 20%. The developments of effective and
preventive agents are critical to control the current public health burden imposed by HCV infection. Lactoferrin in
general and camel lactoferrin specifically has been shown to have a compatitive anti-viral activity against hepatitis C
virus (HCV). The purpose of this study was to examine and compare the anti-infectivity of native human, camel,
bovine and sheep lactoferrin on continuous of HCV infection in HepG2 cells.
Material and methods: Used Lfs were purified by Mono S 5/50 GL column and Superdex 200 5/150 column. The
purified Lfs were evaluated in two ways; 1. the pre-infected cells were treated with the Lfs to inhibit intracellular
replication at different concentrations and time intervals, 2. Lfs were directly incubated with the virus molecules
then used to cells infection. The antiviral activity of the Lfs were determined using three techniques; 1. RT-nested
PCR, 2. Real-time PCR and 3. Flowcytometric.
Results: Human, camel, bovine and sheep lactoferrin could prevent the HCV entry into HepG2 cells by direct
interaction with the virus instead of causing significant changes in the target cells. They were also able to inhibit virus
amplification in HCV infected HepG2 cells. The highest anti-infectivity was demonstrated by the camel lactoferrin.
Conclusion: cLf has inhibitory effect on HCV (genotype 4a) higher than human, bovine and sheep lactoferrin.
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The hepatitis C virus (HCV) is a major health problem in
the world and a leading cause of chronic liver disease [1]
and with an estimated about 180 million people is infected
worldwide. HCV is currently the most significant public
health problem in Egypt with an infection prevalence of
up to 20%, this is ten times greater than any other country
in the world and the highest prevalence of HCV genotype
4, which is responsible for 90% of infections, with a pre-
dominance of subtype 4a (55%) [2-4]. Studies suggest that* Correspondence: redwan1961@yahoo.com
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distribution, and reproduction in any mediummortality related to HCV infection will increase over in
the next two decades [5]. A protective vaccine against
HCV does not exist till now, and current standard treat-
ment for chronic HCV infection is interferon α alone or in
combination with ribavirin. This treatment of HCV is
costly, requires more time (12–72 weeks) to complete,
and has serious adverse effects of ribavirin is hemolytic
anemia that may require dose reduction, low efficiency
and discontinuation of treatment. The developing new
treatment against HCV has been hampered by difficulties
in replicating the virus in cell culture and the lack of suit-
able animal models.
Lactoferrin (Lf) is an 80 kDa multifunctional glycopro-
tein belonging to the transferrin family. Lf is primarily
present in milk, and is also found in other biological fluids,
such as saliva, tears, bile and pancreatic juice [6]. It has
been widely documented that Lf displays antimicrobialentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.









Figure 1 12% SDS-PAGE analysis of different types of purified
Lfs (hLf, cLf, bLf and sLf). Lanes 1–4 purified human, camel, bovine
and sheep lactoferrin, respectively.
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tivity was attributed to its ability, to bind iron with a high
affinity and unlike transferrin, retain its bound iron under
acidic conditions. Also Lf is considered to be a part of the
innate immune system and takes part in specific immune
reactions, but in an indirect way [7]. The antiviral activity
of Lf is directed against a broad spectrum of viruses, in-
cluding both RNA- and DNA-viruses, enveloped as well
as naked viruses. Lf saturated with iron ions has been
shown to exhibit antiviral activity against HSV-1 and
HSV-2 [8,9]. Lf also exhibit antiviral properties against
HCV. Ikeda et al. [10] have shown that Lf is able to pre-
vent the infection of HCV in the cultured human hepato-
cytes cell line PH5CH8. Since pre-incubation of Lf and
HCV was required to prevent infection of the cells it was
hypothesized that the inhibition happens through a direct
interaction between the virus and Lf. This idea is sup-
ported by the fact that pre-incubation of the PH5CH8
cells with Lf had no inhibitory effect on HCV, indicating
that the antiviral activity of Lf against HCV was not due to
the interaction of Lf with the cells.
Bovine and human Lfs are able to bind to the HCV en-
velope proteins E1 and E2 [11]. This binding inhibits any
possible interaction of the virus with its cellular receptors.
In all cases studied, it appears that Lf exerts its antiviral
activity at an early phase in the infection process. Similar
results have recently been reported for camel lactoferrin
(cLf), demonstrating complete inhibition of virus entry
when cLf and HCV were preincubated together, while Lf
pre-incubation with human leukocytes [12], HepG2 cells
[13] and Huh7.5 cells [14,15] prior to HCV infection had
no effect on viral entry. Both full length of native and
recombinant clf were shown similar results [14]. The enzym-
atic prepared of native N- lobe, C-lobe and recombinant N-
lobe has been shown a similar effect against HCV cellular
infectivity [14]. Several viral pathogens has been shown to
use host cell surface HS as an attachment receptor during
the infection process and Lf also binds HS [16]. The results
have shown that HS at the cell surface is important for Lf to
exert antiviral activity [17,18]. The objective of this study was
to examine and comparison the potential inhibitory effects of
human, camel, bovine and sheep lactoferrin on HCV entry
and amplification in HepG2 cells.
Results
Purification of native Lfs
Human, Camel, Bovine and Sheep lactoferrins were iso-
lated and purified in two steps with cation exchange resin
(Mono S 5/50 GL column) and gel filtration chromatog-
raphy (Superdex 200 5/150 column). The skimmed milk
by was loaded to Mono S 5/50 GL column and the Lfs
were eluted at a salt strength of 0.0-1.0 M NaCl. The peak
containing Lf was concentrated and applied into Superdex
200 5/150 column. Only one band was visualized on 12%SDS-PAGE of the protein for all Lfs. The electrophoretic
analysis of the protein eluted revealed that the presented a
single protein band corresponding to about 80 KDa
(Figure 1) without clear differences in the molecular
weight of all lactoferrins.
Cytotoxic effect of hLf, cLf, bLf and sLf
To exclude the possibility that the elimination of the HCV
was caused by the reduced viability of the cells, the cyto-
toxic effects of Lfs on the cells were investigated. PBMCs
and HepG2 cells were treated with each protein at con-
centrations of 0.5 and 1.0 mg/ml for 4 days. Cell viability
was compared with that of untreated PBMCs and HepG2
cells. The results showed that all used Lfs had no adverse
effects on the viability of PBMCs at concentrations of 0.5
or 1.0 mg/ml after incubation for 4 days as shown in
Table 1. While in case of HepG2 cells, the viability was re-
duced to around 90% only after 4 days of incubation at
concentrations of 0.5 or 1.0 mg/ml for all used Lfs as
shown in Table 1.
Inhibition Potential of hLf, cLf, bLf and sLf
All the Lfs used were demonstrated ability to completely
inhibit HCV particles entry into HepG2 cells at concentra-
tion of 1.0 mg/ml. HepG2 cells (105) were cultured in du-
plicate as described in materials and methods section. The
cells were inoculated with HCV infected sera pretreated
with each Lf alone at concentrations of 0.25, 0.5 and
1.0 mg/ml for 60 min and cultured for seven days. The
Table 1 Cell viability of lactoferrin forms by MTT method
HepG2 Cells PBMCs
0.5 mg/ml 1.0 mg/ml 0.5 mg/ml 1.0 mg/ml
Control 100 100 100 100
Camel Lf 92 89 100 100
Human Lf 95 90 100 100
Bovine Lf 94 88 100 100
Sheep Lf 91 88 100 100
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HCV non coding sequence in comparison to the positive
and negative control. The result revealed that the clf, was
able to completely inhibit the HCV entry into HepG2 cells
at concentrations of 0.5 and 1.0 mg/ml. While the results

















Figure 2 Prevention of HCV entry into HepG2 cells by different types
control (HepG2 cells served as negative control); lane 3, positive control (in
comparison among different Lfs at concentration of 0.25 mg/ml (A), 0.5 mg
served as internal control.cLf to completely inhibit the HCV entry into cells at con-
centration of 1.0 mg/ml only, but at concentrations
0.25 mg/ml for all used Lfs were failed to prevent or block
HCV particles from entry into HepG2 cells as shown
in Figure 2.
Effect of hLf, cLf, bLf and sLf on intracellular
replication of HCV
Using RT-nested-PCR
In order to determine the inhibitory effects of Lf on HCV
replication in infected HepG2 cells, Lf treatment was
performed at different concentrations. Results showed that
cLf, hLf, bLf and sLf effectively inhibit HCV replication in
infected HepG2 cells. hLf, bLf and sLf at concentrations of
0.25 and 0.5 mg/ml and cLf at concentrations of 100, 150,


























of Lfs (hLf, bLf, cLf and sLf). Lane 1, DNA ladder; lane 2, negative
fected HepG2 cells with HCV served as positive control); lanes 4–7,
/ml (B) and 1.0 mg/ml (C), as indicated under the gel graph. Rluc
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HepG2 cells. Camel Lf has the ability to inhibit HCV rep-
lication at concentrations starts from 200, 250 and
500 μg/ml after four days of treatment, but cLf at concen-
trations of 100 and 150 μg/ml was failed to block the
HCV replication inside the infected cells as shown in
Figure 3. However, human, bovine and sheep Lfs were able
to completely inhibit the replication of HCV at concentra-
tion starts from 0.5 mg/ml, while at concentration of
0.25 mg/ml, those proteins were failed to prevent HCV
replication inside infected HepG2 cells as shown in
Figure 4.
Using real time PCR
The results were indicated that the camel lactoferrin at
all concentrations used was able to prevent HCV parti-
cles from replication inside HepG2 cells completely as
shown in Table 2. The activity of bovine lactoferrin be-
came 100% at concentration 0.5 and 0.75 mg/ml and
drastically declined to become 7.28% at concentration of
0.25 mg/ml. However, sheep Lf was able to complete in-
hibition of HCV replication inside infected HepG2 cells
with relative activity 100% at concentrations of 0.5 and
0.75 mg/ml and the activity was decreased to become
16.73% at concentration of 0.25 mg/ml (Table 2). While
the activity of human lactoferrin on HCV replication in-
side infected HepG2 cells decreased from 100% at con-
centrations of 0. 5 and 0.75 mg/ml to become 24.48% at
concentration of 0.25 mg/ml as shown in Table 2.
Using flow cytometry
The obtained results using flowcytometery were confirma-
tive for the above results through evaluation of the effect
of the lactoferrin forms on intracellular burden and may
tracing the HCV by the indirect intracellular immuno-
staining of HCV antigens with the flowcytometry. Camel
Lf could inhibit the replication of HCV at concentrations





Figure 3 Inhibition of HCV amplification in infected HepG2 cells by ca
lane 2, negative control (HepG2 cells served as negative control); lane 3, po
control); lane 4–7, comparison among different concentrations of cLf. Rluc(Figure 5). However, human, bovine and sheep Lfs were
accomplished their HCV replication inhibition at 0.5 mg/
ml concentration as detected high fluorescence signal in
FACS scan profile (Figure 5).
Discussion
Lactoferrin is an iron binding protein, which a member of
the transferrin family present mainly in breast milk and in
lower extent in bile, tears and in other exocrine secretions.
However, Lf is also found in plasma derived from predom-
inantly neutrophil secondary granules, release of which in-
creases during inflammation. Breast milk contains several
components with antimicrobial activity. The most one with
antiviral activity detected in milk can be ascribed to Lf
[15,19,20]. The antiviral activity of Lf is directed against a
broad spectrum of viruses, including both RNA- and
DNA-viruses. Because of the importance of HCV as a hu-
man pathogen and the lack of an effective treatment or
protective vaccine [21,22], there is a crucial need to screen-
ing new compounds having anti-HCV activity with lower
side effects. Previously we have shown that camel lactofer-
rin inhibits HCV genotype 4 from entry to PBMC, HepG2
and HepG2 cells and cLf has also been shown to inhibit
the HCV G4 replication inside infected cells [12-15,20]. In
the current study, we were tested and compared the inhibi-
tory effect of hLf, bLf, cLf and sLf against HCV G4.
This is the first study showing that the entry of HCV G4
to HepG2 cells and the replication of the virus inside it are
prevented by hLf, cLf, bLf and sLf. The results demon-
strated that the cLf displayed its effective inhibition against
HCV entry as well as replication in infected HepG2 cells
more than hLf, bLf and sLf. Current study indicated that
the cLf inhibit the HCV entry into HepG2 cells at concen-
trations of 0.5 and 1.0 mg/ml, while hLf, bLf and sLf have
the same ability of cLf to inhibit the HCV entry into cells
but at concentration of 1.0 mg/ml, whereas they were
failed to inhibit the entry of the virus into cells at concen-
tration of 0.25 mg/ml. However, at all concentrations the         5            6           7
Rluc
HCV
        150         200      250
µg/ml
mel lactoferrin at different concentrations. Lane 1, DNA ladder;
sitive control (infected HepG2 cells with HCV served as positive
served as internal control.








































Figure 4 Inhibition of HCV amplification in infected HepG2 cells by different types of Lfs. Lane 1, DNA ladder; lane 2, negative control
(HepG2 cells served as negative control); lane 3, positive control (infected HepG2 cells with HCV served as positive control); lane 4–7, comparison
among different types of LFs at concentration of 0.25 mg/ml (A) and 0.5 mg/ml (B). Rluc served as internal control.
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side the HepG2 cells, The activity of hLf decreased from
100% at concentrations of 0.5 and 0.75 mg/ml to became
24.48% at concentration of 0.25 mg/ml, and bLf activity was
decreased from 100% at concentration 0.5 and 0.75 mg/ml
to became 7.28% at concentration of 0.25 mg/ml. Whereas,Table 2 Quantitation in vitro comparison among different
types of LFs (human, bovine, camel and sheep) activity






control Positive 100410 0.0
Negative 0.0 100
Human LF 0.25 75820 24.48
0.5 0 100
0.75 0 100
Bovine LF 0.25 93100 7.28
0.5 0 100
0.75 0 100
Camel LF 0.25 0 100
0.5 0 100
0.75 0 100
Sheep LF 0.25 83610 16.73
0.5 0 100
0.75 0 100sLf was able to inhibit HCV replication inside infected
cells with relative activity of 100% at concentrations of 0.5
and 0.75 mg/ml and its activity was 16.73% at concentra-
tion of 0.25 mg/ml.
The HCV inhibition potential was simultaneously ana-
lyzed at viral RNA level (by RT-nested-PCR, real time
PCR) and furthermore, using the highly sensitive intracel-
lular staining for detection of the specific viral proteome.
It seems that the flow cytomtery could exactly show the
dose dependent decrease of the intracellular viral signals,
and confirm the RNA viral load [23] through the ability to
count the rate of infected cells directly. It precisely, when
a typical forward and side scatter was classified to differen-
tiate stained and non-stained cells or specific and
non-specific immunofluorescence signals, was clear corre-
lations between the flow cytometry and RT-PCR/real-time
PCR. This approach appeared to be useful and dependable
for anti-HCV agent discovery and/or their follow up
[12,24]. Our findings are consistent with several previ-
ous studies, those using human and bovine lactoferrin
to inhibit HCV (genotype1) entry into the PH5CH8
cell-line [25,26].
Many viruses are inhibited by Lf, which exhibits its anti-
viral activity at early stage of infection, most probably
through preventing virus entry by interacting with the
viral attachment receptor heparan sulfate [17,18,27,28].
However, the blocking of viral binding receptors on the
cell surface cannot fully explain the antiviral activity of Lf
Figure 5 (See legend on next page.)
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Figure 5 Histograms from gated cells obtained from flowcytometric analysis of HCV-infected HepG2 cells and treated with Lf forms.
Infected HepG2 cells with HCV served as positive control (P) and HepG2 cells served as negative control (N). Cells were stained intracellularly with
anti-rabbit antibody conjugated with FITC. Effect of camel, bovine, human and sheep Lf (A, B, C and D) at concentrations of 0.20 and 0.5 mg/ml
(1 and 2), respectively. M1 is positive stained cells.
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on picornavirus infection with different results. Marchetti
et al. [30] demonstrated that bLf and hLf inhibited the
early phases of poliovirus infection, whereas they were in-
effective when added after the viral adsorption step. Suc-
cessively, it was reported that hLf did not affect rhinovirus
replication [31], while bLf exerted an inhibitory effect on
enterovirus 71 attachment to target cells [32]. Camel Lf
has three characteristics which make it unique over Lf of
other species: 1) some critical residues such as Pro418,
Leu423, Lys433, Gln651, Gly629, Lys637, Arg652, and
Pro592 related to domain movement are different in cLf
from those found in other Lf species, indicating of specific
structural-related differences, 2) cLf loses 50% of its iron
contents at pH 6.5 and the remaining 50% is lost at acidic
condition (pH 4.0-2.0). The N-lobe lost iron at acidic pH
less than 4.0, whereas the C-lobe lost iron at pH 6.5, which
indicating a difference in the iron release mechanism from
the two lobes, 3) the entirely difference in predicated gly-
cosylation sites in cLf from other species. These data dem-
onstrate that the cLf acts as half lactoferrin “iron binding
protein” and half transferring “irontransporter protein”, un-
like other lactoferrins and transferrins [33]. A recent study
showed that the therapy with bovine Lf lead to lipid peroxi-
dation inhibition [34]. In accordance, the camel Lf main-
tains a dual function; 1) it inhibits lipid peroxidation and 2)
it regulates the hepatic iron content through its ability to
bind and transport the iron at acidic and basic pHs.
Conclusions
In Conclusion, we demonstrated, for the first time, that
the camel lactoferrin has inhibitory activity on HCV
(genotype 4a) double folds higher than human, bovine
and sheep lactoferrin. However, the question still needs
further analysis, why the camel lactoferrin has this su-
periority? Is it structure dependent, i.e. protein and/or
carbohydrates wise?
Materials and methods
Processing of milk and lactoferrin purification
Milk from camels (Camelus dromedarius) was pur-
chased from ALKHIR camel farm (Matrouh, Egypt) and
transferred frozen to our laboratory, Bovine and sheep
milk were purchase from local market and human was
obtained from 10 healthy feeding mothers. A solution of
sodium azide (0.2%) containing 5 mM EDTA and 5 mM
PMSF was added to the milk before defatting by centri-
fugation at 1000 × g for 30 min at 4°C. The pH ofskimmed milk was decreased to 4.2 with 1 M HCl to pre-
cipitate the casein [13,20]. Skimmed milk was used for Lf
purification and diluted with 50 mM Tris–HCl, pH 8.0
then samples containing 100 mg protein was applied to
Mono S 5/50 GL column (5 × 50 mm, GE Health care,
Sweden) previously equilibrated with 50 mM tris HCl,
pH 8.0 and column was washed with same equilibrated
buffer to remove impurities. The elution was carried out
with 50 mM tris HCl, pH 8.0 and gradient from 0.0 to
1.0 M NaCl at flow rate of 1.0 ml/min and fraction size of
1.0 ml/fraction using AKTA prime plus FPLC (GE Health
care, Sweden). The fractions containing Lf were collected
and concentrated by amicon ultrafiltration cell (Amicon
8200 Pmax 75 psi, 5.3 Kg/cm2 using 50 kDa MWCO
Amicon filter membrane (Millipore, Billerica, USA), then
samples containing 0.8 mg protein was applied to
Superdex 200 5/150 column (5 × 150 mm, GE Health care,
Sweden) previously equilibrated with 50 mM tris HCl,
pH 8.0. Elution of all Lfs was carried out with same equili-
brated buffer at flow rate of 0.3 ml/min and fraction size
of 0.5 ml/fraction. The fractions containing Lf were con-
centrated by amicon ultrafiltration cell using 50 kDa
MWCO Amicon filter membrane (Millipore, Billerica,
USA). The Lfs purity was confirmed by SDS-PAGE [35].
Protein and endotoxin determination
Protein was determined either by measuring the absorb-
ance at 280 nm or by the method of Bradford [36] using
bovine serum albumin as a standard protein. The endo-
toxin level of the purified lactoferrin was checked [37]
to avoid its pyrogenic effects on the cell-culture system.
All lactoferrin batches used were free of endotoxin (data
not shown).
Infected serum samples
For all infection experiments, PCR-HCV positive serum
samples of genotype 4 from Egyptian patient “A.R.” (After
approval from our Genetic Engineering and Biotechnology
Research Institutes (GEBRI) institutes ethics committee)
were used as previously described by Redwan and Tabll
[12-15,38,39]. Written informed consent was obtained
from the patient for the publication of this report and any
accompanying images.
Cytotoxic effect of lactoferrin forms
The cytotoxicity of the purified Lfs on human separated
PBMCs and HepG2 was examined by the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
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HepG2 cells in 200 μl complete media were plated in 96-
well microtiter plates and cultured for overnight at 37°C
before treatment with Lf forms, then the medium
was refreshed with new DMEM supplemented medium
containing 1.0 mg/ml or 0.5 mg/ml of protein. The cells
were incubated for four days at 37°C. After incubation, the
cells were washed 3 times with PBS, and 200 μl MTT solu-
tion (0.5 mg/ml in PBS) was added to each well. After in-
cubation for 3–5 h at 37°C, 5% CO2, the medium was
discarded and the wells were dried. Formazan crystals
were resuspended in 200 μl dimethyl sulfoxide, followed
by shaking for 5 min to thoroughly mix the formazan into
the solvent. The optical density was read at 570 nm. The
relative cell viability (%) compared to control wells
containing cells without adding Lf was calculated using
the following formula: (A) test/ (A) control × 100%.
In vitro comparison of neutralizing efficacy of different
forms of lactoferrin
Inhibition potential of the lactoferrin forms
To examine the interaction of hLf, cLf, bLf and sLf with
HCV, 1 ml of infected serum and lactoferrin forms (final
concentration at 0.25, 0.5 and 1.0 mg/ml) was pre-
incubated with DMEM media containing 2% HCV infected
serum for 1 h at 4°C, and then the mixture of HCV and
hLf, cLf, bLf or sLf was added to HepG2 (1.0 × 105) cells
cultured in 24-well microtiter plate, and incubated for
90 min at 37°C, 5% CO2 and 88% humidity. The cells were
washed three times with 1 ml of PBS and further incubated
for 7 days at 37°C, 5% CO2 and 88% humidity. (Positive
HepG2 (1.0 × 105) cells were infected with HCV and nega-
tive HepG2 (1.0 × 105) cells only without infection) control
cultures were included. The cells were washed three times
from debris and dead cells by using DMEM supplemented
media or 1 × PBS, followed by total RNA extraction
[12-15,38].
Effect evaluation of the different lactoferrin on hepatitis C
virus intracellular replication
HepG2 cells were washed twice in DMEM supplemented
media. The cells were suspended at 1.0 × 105 cells/ml in
DMEM culture media (DMEM supplemented media, 10%
fetal bovine serum (FBS); 100 U of penicillin and 100 μg
streptomycin). The cells were left to adhere on 24-well
plates for 24 h at 37°C, 5% CO2 and 88% humidity, then
infected with HCV-infected serum in DMEM media and
incubated for 24 h at 37°C, 5% CO2 and 88% humidity.
The purified cLf, was added at concentrations 100, 150,
200, 250 and 500 μg/ml, while purified hLf, bLf and sLf
were added at concentrations of 0.25 and 0.5 mg/ml. Posi-
tive HepG2 (1.0 × 105) cells were infected with HCV and
negative HepG2 (1.0 × 105) cells only without infection
control cultures were included. The cells were incubatedfor four days at 37°C, 5% CO2 and 88% humidity. After in-
cubation the cells were washed three times from debris
and dead cells by using DMEM supplemented media, then
the cells were tested by RT-PCR and real time PCR.
Isolation and extraction of RNA from HepG2 cells
RNA was isolated from HepG2 cells as previously de-
scribed [14]. Briefly, cells were precipitated by centrifuga-
tion at 1200 rpm for 5 min at 4°C and washed three times
with PBS or basal media to remove adherent viral particles
before lysis in 4 mol/l guanidine isothiocyanate containing
25 mM sodium citrate, 0.5% sarcosyl and 100 mM β-
mercaptoethanol and 100 μl sodium acetate. The lysed
cells were centrifuged at 12000 rpm for 10 min at 4°C. The
aqueous layer was collected and mixed with equal volume
of isopropanol. After incubation at −20°C overnight, RNA
was precipitated by centrifugation at 12000 rpm for 20 min
at 4°C and the precipitate RNA was washed twice with
70% ethanol.
RT-nested-PCR of HCV RNA
Reverse transcription-nested PCR was carried out previ-
ously reported [12-15,38,42]. The complimentary DNA
(cDNA) and the first PCR reaction of the nested PCR de-
tection system for the HCV RNA was performed in a 50 μl
volume single-step reaction using the Ready-To-Go RT-
PCR beads (Amersham Pharmacia Biotech, Pis-cataway,
NJ, USA), 400 ng of total HepG2 cells RNA, 10 μM of the
reverse primer 1CH (for plus strand), 10 μM of the forward
primer 2CH (for minus strand) and 10 μM of reverse pri-
mer P2. The test was incubated at 42°C for 30 min and de-
natured at 98°C for 10 min. Amplification of the highly
conserved 5′-UTR sequences was done using two rounds
of PCR with two pairs of nested primers (Clontech, USA).
First round amplification was done in 50 μl reaction mix-
ture, containing 10 μM from each of 2CH forward primer
and P2 reverse primer, 0.2 mmol/l from each dNTP, 5 μl
from RT reaction mixture as template and 2 U of Taq
DNA polymerase (Promega, Madison, USA) in a 1× buffer
supplied with the enzyme. The thermal cycling protocol
was as follows: 1 min at 94°C, 1 min at 55°C and 1 min at
72°C for 30 cycles. The second round amplification was
done similar to the first round, except for use of the nested
reverse primer D2 and forward primer F2 at 10 μM each. A
fragment of 174 bp was identified in positive samples. Pri-
mer sequences were as follows: 1CH: 5′-GGTGCACGGTC
TACGAGACCTC-3′, 2CH: 5′-AACTACTGTCTTCACG
CAGAA-3′, P2: 5′-TGCTCATGGTGCACGGTCTA-3′,
D2: 5′- ACTCGGCTAGCAGTCTCGCG-3′ and F2: 5′-G
TGCAG CCTCCAGGACCC-3′. To control false detec-
tion of negative-strand HCV RNA and known variations
in PCR efficiency, specific control assays and rigorous
standardization of the reaction were employed. The ampli-
fication process was included a Rulc plasmid as internal
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through 3% agarose gel and ethidium bromide was used
to visualized 174 bp for HCV and 374 bp of Rluc.Real time PCR to evaluation of antiviral activity of the clf,
recombinant clf, N-lobe, recombinant N-lobe and C-lobe
against HCV
We used real time PCR to examine the ability of hLf, clf,
bLf and sLf at concentrations of 0.25, 0.5 and 0.75 mg/ml
to prevent replication of HCV particles inside HepG2
cells. Briefly, infected HepG2 cells with HCV were treated
with those proteins and cultured as described above. After
incubation of HepG2 cells at suitable time the cells were
washed three times from debris and dead cells by using
PBS then HCV RNA was isolated and extracted from
HepG2 cells by INSTANT Virus RNA Kit (AJ Roboscreen
GmbH). Amplification of HCV RNA in samples and stan-
dards is measured by RoboGene HCV RNA Quantifica-
tion Kit (AJ Roboscreen GmbH) use Rotor-Gene real time
PCR machine (Corbett life Science, QIAGEN Company,
model number R0708103) and report generated by Rotor-
Gene Q Series Software 1.7 (Build 94) Copyright 2008
Corbett Life Science, a QIAGEN Company.
Detection of intracellular HCV by flow cytometry
In this test Flow cytometry was used to evaluate the anti-
viral activity of the purified proteins (hLf, cLf, bLf and
sLf). The HepG2 cells were suspended at 1.0 × 105 cells/
ml in DMEM culture media. The cells were infected with
HCV-infected serum and incubated for 24 h at 37°C, 5%
CO2 and 88% humidity. The purified Lf forms were added
at concentrations of 0.25 and 0.5 mg/ml. Positive HepG2
(1.0 × 105) cells were infected with HCV and negative
HepG2 (1.0 × 105) cells only without infection control cul-
tures were included. The cells were incubated for four
days at 37°C, 5% CO2 and 88% humidity. The cells were
washed three times from debris and dead cells by using
1.0 × PBS. Intracellular labeling was performed by indirect
immunofluorescence. Cells were centrifuged and superna-
tants were removed. Cell pellets were washed twice with
1.0 × PBS containing 1% normal goat serum (2% bovine
serum albumin), cells were incubated with 4% paraformal-
dehyde for 10 min and 0.1% Triton X-100 in Tris buffer
(pH 7.4) for 6 min. After washing three times with 1.0 ×
PBS, the cells were incubated with monoclonal antibody
against HCV core (1:1,000) was added to the cell suspen-
sion and incubated at room temperature for 1 h
[14,15,39]. Then, the cells were washed three times with
1.0 × PBS and the cells were immunofluorescence stained
with fluorescein-conjugated goat anti-mouse and incu-
bated at 4°C for 30 min. After being washed, the cells were
suspended in 2 ml PBS and analyzed by Flow cytometry
(Partic, Germany) [12,24].Statistical analysis
Most measurements were repeated three times and the
results are presented as the mean plus standard devi-
ation. Data were analyzed by using Student’s t-test.
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